Results 131 to 140 of about 276,512 (289)

Hepatitis A Post Hepatitis A Vaccination? [PDF]

Journal of Travel Medicine, 2006
Prativa Pandey, William Cave, David R. Shlim   +2 more
openaire   +1 more source

Infection Risk From Humans and Animals in the Anatomy Laboratory: A Scoping Review

Clinical Anatomy, Volume 39, Issue 3, Page 346-367, April 2026.
ABSTRACT Whole‐body dissection is a cornerstone of anatomy education. During and following the COVID‐19 pandemic, exposure to infectious agents and other risks of dissection were highlighted. To identify potential risks, one must have the data outlining these risks in specific situations.
Margaret A. McNulty, Elizabeth R. Agosto
wiley   +1 more source

Pacific Australia Labour Mobility Workers in Australia: Lived Experiences of Health and Navigating Health Systems

Health Promotion Journal of Australia, Volume 37, Issue 2, April 2026.
ABSTRACT Objectives Pacific Australia Labour Mobility (PALM) scheme workers (hereafter referred to as PALM participants) are integral to Australia's economic landscape, contributing predominantly to agriculture and meatworks sectors. Many PALM participants come from regions with high burdens of blood‐borne viruses (BBVs) such as hepatitis B virus (HBV),
Geraldine Vaughan, Catherine O'Mullan, Robyn Preston, Haylee Fox   +3 more
wiley   +1 more source

Controlled trial of cervical cancer screening frequency among human‐papillomavirus‐vaccinated women

International Journal of Cancer, Volume 158, Issue 7, Page 1941-1951, 1 April 2026.
What's new? Since the introduction of the human papillomavirus (HPV) vaccine in 2006, vaccine‐type infections have declined markedly. As nonvaccine HPV types generally carry lower oncogenic potential, this shift warrants reevaluation of cervical screening regimens.
Mònica Ortega Llobet, Penelope Gray, Iacopo Baussano, K. Miriam Elfström, Tiina Eriksson, Camilla Lagheden, Pekka Nieminen, Anna Söderlund‐Strand, Joakim Dillner, Ville N. Pimenoff, Matti Lehtinen   +10 more
wiley   +1 more source

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 955-966, April 2026.
In the phase I/IIa GOING trial, an add‐on strategy with regorafenib followed by nivolumab showed a manageable safety profile and meaningful clinical activity in second‐line hepatocellular carcinoma, with a median overall survival of 25 months and 45% three‐year survival in sorafenib‐experienced patients.
Marco Sanduzzi‐Zamparelli, Ana Matilla, José Luis Lledo, Sergio Muñoz‐Martínez, María Varela, Mercedes Iñarrairaegui, Christie Perelló, Beatriz Mínguez, Neus Llarch, Laura Márquez, Antonio Guerrero, Gemma Iserte, Andrés Castaño‐García, Laura Carrión, Marta Fortuny, Jordi Rimola, Ángeles García‐Criado, Gema Domenech, Ferran Torres, José Rios‐Guillermo, Loreto Boix, Esther Samper, Àngels Kateb, Jordi Bruix, Maria Reig   +24 more
wiley   +1 more source

Immunogenicity persistence in children of hepatitis A vaccines Healive® and Havrix®: 11 years follow-up and long-term prediction. [PDF]

Hum Vaccin Immunother, 2020
Wang Y, Qi Y, Xu W, Hu Y, Wang L, Yu Y, Jiang Z, Xia J, Zeng G, Wang Y.   +9 more
europepmc   +1 more source

The return of metabolism: biochemistry and physiology of glycolysis

Biological Reviews, Volume 101, Issue 2, Page 751-803, April 2026.
ABSTRACT Glycolysis is a fundamental metabolic pathway central to the bioenergetics and physiology of virtually all living organisms. In this comprehensive review, we explore the intricate biochemical principles and evolutionary origins of glycolytic pathways, from the classical Embden–Meyerhof–Parnas (EMP) pathway in humans to various prokaryotic and ...
Nana‐Maria Grüning, Federica Agostini, Camila Caldana, Johannes Hartl, Matthias Heinemann, Markus A. Keller, Jan Lukas Krüsemann, Costanza Lamperti, Carole L. Linster, Steffen N. Lindner, Julia Muenzner, Jens Nielsen, Zoran Nikoloski, Bettina Siebers, Jacky L. Snoep, Hezi Tenenboim, Bas Teusink, Spencer J. Williams, Mirjam M. C. Wamelink, Markus Ralser   +19 more
wiley   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

European Journal of Haematology, Volume 116, Issue 4, Page 336-349, April 2026.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot, Frederic Baleydier, Laure Pittet, Geraldine Blanchard‐Rohner   +3 more
wiley   +1 more source